JP2022535072A5 - - Google Patents
Info
- Publication number
- JP2022535072A5 JP2022535072A5 JP2021571744A JP2021571744A JP2022535072A5 JP 2022535072 A5 JP2022535072 A5 JP 2022535072A5 JP 2021571744 A JP2021571744 A JP 2021571744A JP 2021571744 A JP2021571744 A JP 2021571744A JP 2022535072 A5 JP2022535072 A5 JP 2022535072A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- peaks
- xrpd pattern
- theta scale
- following
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856404P | 2019-06-03 | 2019-06-03 | |
| US62/856,404 | 2019-06-03 | ||
| PCT/US2019/065980 WO2020247019A1 (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of a kinase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535072A JP2022535072A (ja) | 2022-08-04 |
| JP2022535072A5 true JP2022535072A5 (cg-RX-API-DMAC7.html) | 2022-12-19 |
| JP7579281B2 JP7579281B2 (ja) | 2024-11-07 |
Family
ID=69160360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571744A Active JP7579281B2 (ja) | 2019-06-03 | 2019-12-12 | キナーゼ阻害剤の結晶性塩形態 |
Country Status (22)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| AU2022420610A1 (en) | 2021-12-22 | 2024-06-27 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| SG187064A1 (en) * | 2010-07-14 | 2013-02-28 | Zhejiang Beta Pharma Inc | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| MX2019012505A (es) * | 2017-05-26 | 2019-12-19 | Exelixis Inc | Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 KR KR1020217041796A patent/KR102826380B1/ko active Active
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 EP EP19836340.0A patent/EP3976587B1/en active Active
- 2019-12-12 GE GEAP201915849A patent/GEP20247655B/en unknown
- 2019-12-12 ES ES19836340T patent/ES3008963T3/es active Active
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 GE GEAP202415849A patent/GEAP202415849A/en unknown
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/en not_active Ceased
- 2019-12-12 AU AU2019449809A patent/AU2019449809B2/en active Active
- 2019-12-12 PH PH1/2021/553020A patent/PH12021553020A1/en unknown
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
- 2019-12-12 JP JP2021571744A patent/JP7579281B2/ja active Active
- 2019-12-12 CA CA3139148A patent/CA3139148A1/en active Pending
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
-
2021
- 2021-10-20 ZA ZA2021/08034A patent/ZA202108034B/en unknown
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106795144B (zh) | 用于调节egfr突变体激酶活性的化合物和组合物 | |
| DK2383268T3 (en) | PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors | |
| JP2011515370A (ja) | 4−アミノ−5−フルオロ−3−[5−(4−メチルピペラジン−1−イル)−1h−ベンズイミダゾール−2−イル]キノリン−2(1h)−オン乳酸塩の結晶形態及び2つの溶媒和物形態 | |
| JP2015510890A5 (cg-RX-API-DMAC7.html) | ||
| JP6896701B2 (ja) | イミダゾリルアミド誘導体 | |
| KR102142797B1 (ko) | 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도 | |
| TW200932727A (en) | New acetyl coenzyme a carboxylase (ACC) inhibitors and uses in treatments of obesity and diabetes mellitus | |
| JP2020511515A5 (cg-RX-API-DMAC7.html) | ||
| JP2010505961A5 (cg-RX-API-DMAC7.html) | ||
| KR20180117697A (ko) | 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도 | |
| KR20100131007A (ko) | 레닌 억제제로서의 3,4-치환된 피페리딘 유도체 | |
| AU2022205604A1 (en) | Selective inhibitors of rock1 and rock2 protein kinases and uses thereof | |
| KR20200011388A (ko) | Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물 | |
| TW201840533A (zh) | 熱休克蛋白90抑制劑 | |
| JPWO2009041559A1 (ja) | インダゾールアクリル酸アミド化合物 | |
| US10138221B2 (en) | Salts of nilotinib and polymorphs thereof | |
| KR20180011772A (ko) | 신규 아미도헤테로아릴 아로일 히드라지드 에틴 | |
| JP2019529553A (ja) | 結晶形 | |
| JP2021523120A5 (cg-RX-API-DMAC7.html) | ||
| JP2023539635A (ja) | ヒストンリジンデメチラーゼ阻害のための化合物、組成物および方法 | |
| KR102205619B1 (ko) | 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 | |
| CN106573928A (zh) | 2‑氨基噻唑衍生物或其盐 | |
| CN103570673B (zh) | 一种甲磺酸伊马替尼α晶型的制备方法 | |
| TH2101007514A (th) | รูปแบบของเกลือที่เป็นผลึกของสารยับยั้งไคเนส | |
| WO2010083720A1 (zh) | 光学纯喹唑啉类化合物 |